{"filing":{"accession_number":"0001193125-26-345722","cik":"0001907108","ticker":"LXEO","company_name":"Lexeo Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"lxeo-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/lxeo-20260812.htm"},"events":[{"id":27017,"run_id":24583,"accession_number":"0001193125-26-345722","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Lexeo Therapeutics issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including net losses of $25.9M and $46.1M respectively, R\u0026D expenses of $19.0M and $34.7M respectively, G\u0026A expenses of $9.0M and $15.6M respectively, and a cash position of $234.2M, along with material clinical program updates including SUNRISE-FA 2 initiation and RMAT designation for LX2020.","company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28354,"accession_number":"0001193125-26-345722","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Lexeo Therapeutics issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including R\u0026D expenses ($19.0M and $34.7M respectively), G\u0026A expenses ($9.0M and $15.6M respectively), net loss ($25.9M and $46.1M respectively), and cash position ($234.2M). The disclosure includes selected financial statements and is a standard quarterly earnings announcement with operational highlights, making it a classic earnings_release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:05:03.280185+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28355,"accession_number":"0001193125-26-345722","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 8.01 disclosure references an updated corporate presentation posted on August 12, 2026, but the substantive content disclosed is Lexeo's second quarter 2026 financial results and operational highlights, as evidenced by the attached press release (EX-99.1) titled \"Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights.\" The filing includes detailed financial statements showing Q2 2026 net loss of $25.9 million, R\u0026D expenses of $19.0 million, and cash position of $234.2 million, along with material clinical program updates (SUNRISE-FA 2 initiation, RMAT designation for LX2020). This is a standard earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:05:03.280185+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28354,"accession_number":"0001193125-26-345722","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Lexeo Therapeutics issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including R\u0026D expenses ($19.0M and $34.7M respectively), G\u0026A expenses ($9.0M and $15.6M respectively), net loss ($25.9M and $46.1M respectively), and cash position ($234.2M). The disclosure includes selected financial statements and is a standard quarterly earnings announcement with operational highlights, making it a classic earnings_release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:05:03.280185+00:00","company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","filing_date":"2026-08-12"},{"id":28355,"accession_number":"0001193125-26-345722","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 8.01 disclosure references an updated corporate presentation posted on August 12, 2026, but the substantive content disclosed is Lexeo's second quarter 2026 financial results and operational highlights, as evidenced by the attached press release (EX-99.1) titled \"Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights.\" The filing includes detailed financial statements showing Q2 2026 net loss of $25.9 million, R\u0026D expenses of $19.0 million, and cash position of $234.2 million, along with material clinical program updates (SUNRISE-FA 2 initiation, RMAT designation for LX2020). This is a standard earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:05:03.280185+00:00","company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","filing_date":"2026-08-12"}]}